Ibogaine banishes PTSD, small study finds
A small Nature-reported study of U.S. Special Forces veterans who traveled to Mexico for ibogaine treatment found self-reported PTSD, depression and traumatic brain injury symptoms dropping by more than 80% after one month. Commenters see the results as intriguing but emphasize that this was an uncontrolled observational study of a cardiotoxic, Schedule I drug, making placebo effects, selection bias and safety risks major concerns. The thread situates ibogaine within the wider psychedelic-therapy and drug-policy landscape, touching on barriers to clinical trials, the war on drugs, pharmaceutical incentives, and the tension between urgent need for better PTSD/addiction treatments and the requirement for rigorous, ethical evidence.
Study design & limitations
- Many note this is not even a phase I trial but a small, uncontrolled observational study of ~30 special-forces veterans treated in Mexico.
- Lack of control group and blinding is repeatedly criticized, especially given high placebo effects in depression and likely expectations from travel, ceremony, and clinician attention.
- Some argue psychedelics are hard or impossible to double-blind; others push back that rigorous controls (e.g., active placebos, anesthesia approaches) are still needed.
- The reported ~80% reduction in symptoms is seen as striking but possibly inflated without proper controls; the headline “banishes PTSD” is viewed as overhyped.
Efficacy, hype, and comparison to other psychedelics
- Commenters recall decades of anecdotal reports that ibogaine helps with addiction (especially opioids) and possibly trauma, and are frustrated by slow formal research.
- Others caution that, for psychedelics generally, effect sizes in depression/anxiety look similar to SSRIs/CBT in better-quality studies; hype is described as a “bubble.”
- There is interest in non-hallucinogenic analogs (e.g., TBG) and in other agents like psilocybin, MDMA, ketamine, DMT.
Safety & risk profile
- Ibogaine is repeatedly flagged as cardiotoxic, associated with QT prolongation and documented sudden deaths, sometimes in people with no known prior heart issues.
- Some say risk can be mitigated with screening, magnesium, and avoiding interacting substances; others cite fatality rates that make it unacceptable for broad use.
- Several warn against self-treatment and emphasize that ibogaine is materially riskier than LSD/psilocybin.
Regulation, funding, and politics
- Strong sentiment that legal barriers and “war on drugs” moralism, not just “red tape,” have delayed research on psychedelics.
- Others highlight economic issues: many of these compounds are hard to patent, so no one wants to fund large, expensive trials.
- Proposals include public funding for non-patentable drugs, patent buyouts, international trial harmonization, and early-access pathways.
PTSD context & broader trauma
- Multiple comments stress that PTSD is common outside the military: train drivers, healthcare workers, abuse survivors, children, call-center workers, etc.
- Some describe standard PTSD treatments (especially exposure-based therapies) and their limits, and express hope but caution that no single drug is a “magic cure.”